SeQure DX Email Format

Biotechnology ResearchMassachusetts, United States2-10 Employees

SeQure DX specializes in precision analytics for gene editing, focusing on evaluating off-target risks to enhance the safety and effectiveness of cell and gene therapies. The company provides a comprehensive suite of assays designed to help developers detect, nominate, and confirm editing outcomes with high sensitivity and in alignment with regulatory expectations. Its customers are therapeutic developers seeking to mitigate editing risks and bolster regulatory confidence throughout discovery and clinical development.

Based in Waltham, Massachusetts, the organization operates with a small specialized team. In January 2025, SeQure DX was acquired by MaxCyte, Inc., and now forms the core of MaxCyte’s Cell & Gene Therapy Services business, offering an integrated solution that combines cell engineering with gene editing risk assessment to support safer and more efficient therapeutic development.

Get verified SeQure DX emails free

Company overview Employee directory